A recent article in the journal Nature Communications describes the structural basis of mimicked HBV/HDV viral peptide drug interaction with its receptor NTCP. HBV, an enveloped DNA virus ...

Infection with hepatitis D viruses causes severe inflammation of the liver. An MHH team has now identified a marker on natural killer cells that is influenced by the anti-inflammatory effectiveness of ...

Gilead Sciences has submitted its marketing application for bulevirtide, its antiviral therapy for rare hepatitis delta virus (HDV) infections, to the FDA. If approved, bulevirtide will be the ...

The proceeds are earmarked mainly for trials of BJT-778, its lead candidate for chronic hepatitis D virus (HDV) infections, but will also support earlier-stage hepatitis B virus (HBV) projects ...

The Food and Drug Administration (FDA) has granted Breakthrough Therapy designation to brelovitug (BJT-778) for the treatment of chronic hepatitis delta (CHD).

including those resulting from the hepatitis D virus (HDV). Concurrently, the company announced an amendment to its collaboration agreement with Gilead (GILD) to indicate an accelerated timeline ...